Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.

Abstract

Objects:

Imigliptin is a novel dipeptidyl peptidase-4 inhibitor. In the present study, we aimed to evaluate the effects of imigliptin and alogliptin on insulin resistance and beta-cell function in Chinese patients with type-2 diabetes mellitus (T2DM).

Methods:

A total of 37 Chinese T2DM patients were randomized to receive 25 mg imigliptin, 50 mg imigliptin, placebo, and 25 mg alogliptin (positive drug) for 13 days. Oral glucose tolerance tests were conducted at baseline and on day 13, followed by the oral minimal model (OMM).

Results:

Imigliptin or alogliptin treatment, compared with their baseline or placebo, was associated with higher beta-cell function parameters (φs and φtot) and lower glucose area under the curve (AUC) and postprandial glucose levels. The changes in the AUC for the glucose appearance rate between 0 and 120 min also showed a decrease in imigliptin or alogliptin groups. However, the insulin resistance parameter, fasting glucose, was not changed. For the homeostatic model assessment (HOMA-β and HOMA-IR) parameters or secretory units of islets in transplantation index (SUIT), no statistically significant changes were found both within treatments and between treatments.

Conclusions:

After 13 days of treatment, imigliptin and alogliptin could decrease glycemic levels by improving beta-cell function. By comparing OMM with HOMA or SUIT results, glucose stimulation might be more sensitive for detecting changes in beta-cell function.

• Authors: Xu Liu, Yang Liu, Hongzhong Liu, Haiyan Li, Jianhong Yang, Pei Hu, Xinhua Xiao, Dongyang Liu
• Journal: Frontiers in endocrinology (Front Endocrinol (Lausanne)) Vol. 12 Pg. 694390 ( 2021) ISSN: 1664-2392 [Print] Switzerland
• PMID: 34616361 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021 Liu, Liu, Liu, Li, Yang, Hu, Xiao and Liu.

Chemical References

• Blood Glucose
• C-Peptide
• Dipeptidyl-Peptidase IV Inhibitors
• Glycated Hemoglobin A
• Imidazoles
• Insulin
• Piperidines
• Pyridines
• Uracil
• imigliptin
• alogliptin

Topics

• Adolescent
• Adult
• Aged
• Blood Glucose (drug effects, metabolism)
• C-Peptide (blood)
• China
• Diabetes Mellitus, Type 2 (drug therapy, metabolism, physiopathology)
• Dipeptidyl-Peptidase IV Inhibitors (pharmacology, therapeutic use)
• Dose-Response Relationship, Drug
• Female
• Glycated Hemoglobin (drug effects, metabolism)
• Humans
• Imidazoles (pharmacology, therapeutic use)
• Insulin (blood)
• Insulin-Secreting Cells (drug effects, physiology)
• Male
• Middle Aged
• Piperidines (pharmacology, therapeutic use)
• Pyridines (pharmacology, therapeutic use)
• Treatment Outcome
• Uracil (analogs & derivatives, pharmacology, therapeutic use)
• Young Adult